Stock STABL STAYBLE THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Stayble Therapeutics AB

Equities

STABL

SE0013513652

Delayed Nasdaq Stockholm
Other stock markets
 05:54:03 31/05/2024 pm IST 		5-day change 1st Jan Change
0.2525 SEK -2.32% Intraday chart for Stayble Therapeutics AB +1.00% -16.67%
21/05 Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
20/02 Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"
AQ
BioStock: Stayble's new analyses of phase IIb study strengthen disc herniation project
AQ
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project
CI
BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation
AQ
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
BioStock: Stayble did not reach the primary endpoint in phase IIb
AQ
BioStock: Stayble Therapeutics presents phase IIb data within one month
AQ
Toleranzia Appoints Successor to Outgoing CFO
MT
BioStock: Stayble reports last patient last visit in the phase IIb study
AQ
Stayble Therapeutics Terminates Liquidity Provider Agreement
MT
BioStock: Stayble enrols the first patient in herniated disc study
AQ
Stayble Enters the First Patient in Herniated Disc Study
CI
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial
MT
BioStock: Progress for Stayble Therapeutics in the second quarter
AQ
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.
CI
BioStock: Stayble's phase IIb study nears the finishing line
AQ
Stayble Therapeutics Phase IIb Study Nears the Final Line
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STABL Stock
  4. News Stayble Therapeutics AB